Savita Rangarajan

Publications

86 publications

Page 3 of 9

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

C. Ross, S. Rangarajan, M. Karimi, G. Toogeh, S. Apte, T. Lissitchkov, S. Acharya, M. J. Manco-johnson, A. Srivastava, B. Brand, B. A. Schwartz, S. Knaub & F. Peyvandi, 2018, Journal of Thrombosis and Haemostasis, 16(2), 253-261

DOI: 10.1111/jth.13923

Type: article

Efficacy and safety of Nuwiq® (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures

N. Zozulya, C. M. Kessler, A. Klukowska, M. Von Depka, K. Hampton, C. R. M. Hay, M. Jansen, J. Bichler, S. Knaub & S. Rangarajan, 2018, Haemophilia, 24(1), 70-76

DOI: 10.1111/hae.13351

Type: article

AAV5–Factor VIII gene transfer in severe hemophilia A

Savita Rangarajan, Liron Walsh, Will Lester, David Perry, Bella Madan, Michael Laffan, Hua Yu, Christian Vettermann, Glenn F. Pierce, Wing Y. Wong & K. John Pasi, 2017, New England Journal of Medicine, 377(26), 2519-2530

DOI: 10.1056/NEJMoa1708483

Type: article

The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders

Víctor Jiménez-Yuste, Rebecca Kruse-Jarres, Savita Rangarajan & Carme Altisent, 2017, Thrombosis and Haemostasis, 116(S 01), S1

DOI: 10.1160/TH16-01-0047

Type: article

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates

Alfonso Iorio, Kathelijn Fischer, Victor Blanchette, Savita Rangarajan, Guy Young & Massimo Morfini, 2017, Thrombosis and Haemostasis, 117(06), 1023-1030

DOI: 10.1160/TH16-12-0942

Type: article

First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

P. Collins, E. Chalmers, J. Alamelu, C. Hay, R. Liesner, M. Makris, M. Mathias, J. Payne, S. Rangarajan, M. Richards, K. Talks, O. Tunstall, M. Williams & D. P. Hart, 2017, Haemophilia, 23(5), 654-659

DOI: 10.1111/hae.13264

Type: article

Targeting of antithrombin in hemophilia A or B with RNAi therapy

K. John Pasi, Savita Rangarajan, Pencho Georgiev, Tim Mant, Michael D. Creagh, Toshko Lissitchkov, David Bevan, Steve Austin, Charles R. Hay, Inga Hegemann, Rashid Kazmi, Pratima Chowdary, Liana Gercheva-kyuchukova, Vasily Mamonov, Margarita Timofeeva, Chang-heok Soh, Pushkal Garg, Akshay Vaishnaw, Akin Akinc, Benny Sørensen & Margaret V. Ragni, 2017, New England Journal of Medicine, 377(9), 819-828

DOI: 10.1056/NEJMoa1616569

Type: article

The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors

Steven R. Lentz, Savita Rangarajan, Faraizah A. Karim, Philip D. Andersen, Per Arkhammar, Gabriela Rosu & Johnny Mahlangu, 2017, Blood Coagulation & Fibrinolysis, 28(3), 224-229

DOI: 10.1097/MBC.0000000000000584

Type: article

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A

Paul Batty, Steve K. Austin, Kate Khair, Carolyn M. Millar, Ben Palmer, Savita Rangarajan, Jan-Phillip Stümpel, Murugaiyan Thanigaikumar, Thynn T. Yee & Daniel P. Hart, 2017, British Journal of Haematology, 176(5), 796-804

DOI: 10.1111/bjh.14543

Type: article

Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study

Kathelijn Fischer, Roshni Kulkarni, Beatrice Nolan, Johnny Mahlangu, Savita Rangarajan, Giulia Gambino, Lei Diao, Alejandra Ramirez-santiago, Glenn F Pierce & Geoffrey Allen, 2017, The Lancet Haematology, 4(2), e75-e82

DOI: 10.1016/S2352-3026(16)30193-4

Type: article

Dr Savita Rangarajan

Connect with Savita

Publications